November 9, 2009 - Chugai Pharmaceutical Co., Ltd. announced today that it obtained approval by the Ministry of Health, Labour and Welfare (MHLW) on 6 November for the additional indication of "Unresectable advanced or recurrent non-squamous non-small cell lung cancer" of its anti-VEGF human monoclonal antibody bevacizumab (genetic recombination).
The details can be read here.
No comments:
Post a Comment